Back to search

Article

Impaired tumor death receptor signaling drives resistance to CAR T cell therapy

2019-05-05

Abstract excerpt

Cellular immunotherapy using T cells engineered to express chimeric antigen receptors targeting CD19 (CART19) leads to long-term remission in patients with B-cell malignancies 1–5 . Unfortunately, a significant fraction of patients demonstrate primary resistance to CART19 or experience relapse after achieving remission. Beyond loss of target antigen, the molecular pathways governing CART19 failure are unknown. He...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
da033d2c-9bdb-5b29-8dd7-0246f49b6f64
DOI
10.1101/627562
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impaired tumor death receptor signaling drives resistance to CAR T cell therapyDOI 10.1101/627562
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionSemantic proximity
Targeting autophagy overcomes cancer‐intrinsic resistance to CAR‐T immunotherapy in B‐cell malignanciesSemantic proximity
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screeningSemantic proximity
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearanceSemantic proximity
Escape From ALL-CARTazSemantic proximity
Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against LeukemiaSemantic proximity
Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemiaSemantic proximity
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.Semantic proximity
Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotypeSemantic proximity
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaSemantic proximity
Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity
Unraveling Cellular and Molecular Mechanisms of Relapse in CD19/CD22 Dual-Targeting CAR T Therapy for B-ALLSemantic proximity
Select a neighboring publication to make it the new centre.